GlassScriptPhysician profile
Bridgett A Cooper
NPI 1518944792
$2,784.65
in general payments reported to CMS, 2019-2025
28 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $139 · 2021: $456 · 2022: $395 · 2023: $288 · 2024: $501 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.38 | 2020-2025 | Ubrelvy, Synthroid |
| Pfizer INC. | $342.65 | 2019-2025 | |
| Abbott Laboratories | $324.52 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $237.78 | 2019-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.64 | 2019-2025 | Jardiance |
| Amgen INC. | $173.89 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $161.40 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $128.06 | 2019-2023 | |
| Glaxosmithkline, LLC. | $118.33 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $96.69 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $93.00 | 2019-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $76.01 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $46.56 | 2019-2025 | |
| Exact Sciences Corporation | $44.28 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $42.33 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.28 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $38.15 | 2019-2024 | Eliquis |
| Hologic Sales and Service, LLC | $33.24 | 2019-2023 | Third Wave, Aptima, Thinprep 2000 Processor |
| Antares Pharma, INC. | $30.28 | 2019-2020 | |
| Neurelis, INC. | $21.56 | 2023 | Valtoco |
| Boston Scientific Corporation | $17.27 | 2025 | Watchman Flx |
| Amarin Pharma, INC. | $16.12 | 2021 | |
| Sumitomo Pharma America, INC. | $15.46 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $15.05 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $14.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.05 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.78 | 2024 | Qelbree |
| Ibsa Pharma INC. | $13.29 | 2024 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgett Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.